Live Chat ×
Skip to main content

Treatment Decision-Making through the Spectrum of MDS: Stem Cell Transplantation

MDS (myelodysplastic syndromes) is a heterogeneous group of malignant hematopoietic stem cell disorders that are characterized by dysplastic and ineffective blood cell production with a variable risk of transformation to acute leukemia. Explaining MDS to patients and their families can be difficult for healthcare professionals (HCPs). The disease process is complex, the prognosis variable, and treatment options must be tailored for each individual patient.

Often the information gap between what HCPs believe they are communicating to their patients and what patients comprehend can be immense. Thus it is imperative that patient-HCP communications are effective to ensure optimal outcomes when managing patients with MDS

Christopher R. Cogle, MD
Associate Professor, College of Medicine, Department of Medicine, Division of Hematology/Oncology
University of Florida Blood & Marrow Transplant Program

Leslie C. Pettiford, RN, BSN, CCRC
Registered Nurse Specialist, Clinical Research Coordinator
University of Florida Health Cancer Center